Abstract
A major limitation in the treatment of cancers is the prevalence of chemoresistant tumors. Chemotherapy agents induce cell death by activating apoptosis. However, most cancer cells express high levels of antiapoptotic proteins and, hence, are chemoresistant. Phenoxodiol, a novel isoflavone derivative, has been shown to induce apoptosis both in vitro and in vivo, even in chemoresistant cancer cells. In addition, phenoxodiol has been shown to chemosensitize resistant cancer cells to commonly used chemotherapy agents, such as carboplatin and paclitaxel. This review will discuss the characterization of phenoxodiol's molecular mechanism and its current state in the clinic.
MeSH terms
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Apoptosis / drug effects*
-
Cell Cycle / drug effects
-
Cell Line, Tumor / drug effects
-
Clinical Trials as Topic / statistics & numerical data
-
Drug Resistance, Neoplasm / drug effects
-
Drug Screening Assays, Antitumor
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use
-
Female
-
Humans
-
Isoflavones / pharmacology
-
Isoflavones / therapeutic use*
-
Lysophospholipids / metabolism
-
Male
-
Models, Biological
-
Neoplasm Proteins / antagonists & inhibitors
-
Neoplasms / drug therapy*
-
Neoplasms / enzymology
-
Neovascularization, Pathologic / drug therapy
-
Sphingosine / analogs & derivatives
-
Sphingosine / metabolism
-
Topoisomerase II Inhibitors
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Isoflavones
-
Lysophospholipids
-
Neoplasm Proteins
-
Topoisomerase II Inhibitors
-
sphingosine 1-phosphate
-
phenoxodiol
-
Sphingosine